Wall Street Zen cuts Denali Therapeutics stock to sell as target averages USD 35.85

Published on 10/15/2026 at 22:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue is USD 12.22 million for the third quarter. Denali Therapeutics stock costs EUR 16.39 on October 15, 2026, up 2.12 percent versus the Frankfurt close.

Analyst view and trading date

MarketBeat reported on October 10, 2026, that Wall Street Zen cut its rating to sell while the average target was USD 35.85.
Denali expects third-quarter revenue of USD 12.22 million for its November 5, 2026 report.
Denali Therapeutics stock costs EUR 16.39 at Lang & Schwarz on October 15, 2026 at 10:01 p.m. CEST, plus 2.12 percent versus the Frankfurt close of October 15, 2026.
Denali had a USD 2.9 billion market capitalization and a 52-week range of USD 13.75 to USD 27.30 on October 15, 2026.

DNLI, US24823R1059, Illustration mit AI erstellt.

Wall Street Zen cut its rating on Denali Therapeutics stock from hold to sell in a report dated October 10, 2026, while the average analyst target stood at USD 35.85, according to MarketBeat. That target was USD 17.51, or 95.42 percent, above the Nasdaq price of USD 18.34 on October 15, 2026 at 4:00 p.m. EDT.

Denali Therapeutics stock was trading at EUR 16.39 at Lang & Schwarz on October 15, 2026 at 10:01 p.m. CEST, up 2.12 percent versus the Frankfurt close of October 15, 2026 at EUR 16.05.

Revenue expectations point to November

The next scheduled report is November 5, 2026, when Denali is expected to publish third-quarter results after the market close. MarketBeat lists consensus revenue of USD 12.22 million and consensus loss of USD 0.37 per share for that period.

The comparison with the second quarter is material. Denali reported USD 3.60 million of revenue and a USD 0.68 loss per share for the second quarter ended June 30, 2026, while the revenue estimate was USD 2.15 million, according to MarketBeat.

Price position after hours

The euro quote sits USD 2.64 above the Nasdaq 52-week low of USD 13.75 when viewed in the home-market currency separately. The Nasdaq range was USD 13.75 to USD 27.30 on October 15, 2026, while volume reached 1,527,686 shares against an average of 1,562,232.

Denali's market capitalization was USD 2.9 billion on October 15, 2026. The price-to-earnings ratio was negative 6.46, reflecting the company's reported loss position.

Comparison with peers

DNLI (Nasdaq, USD): plus 2.12 percent, price-to-earnings ratio negative 6.46, market capitalization USD 2.9 billion.
Ascendis Pharma (Nasdaq, USD): minus 0.17 percent, price-to-earnings ratio 17.64, market capitalization USD 14.1 billion.
Biogen (Nasdaq, USD): plus 1.08 percent, price-to-earnings ratio 41.65, market capitalization USD 34.8 billion.

Closing quote for investors

Denali Therapeutics is a biotechnology company developing medicines for neurodegenerative and lysosomal diseases through its Transport Vehicle platform. The company is listed on Nasdaq under DNLI.

Denali Therapeutics stock was trading at EUR 16.39 at Lang & Schwarz on October 15, 2026 at 10:01 p.m. CEST, plus 2.12 percent versus the Frankfurt close of October 15, 2026 at EUR 16.05. The further course of trading is shown by the continuously updated real-time quote of Denali Therapeutics stock.